Koers Aastrom Biosciences Inc Nasdaq
Aandelen
US00253U4040
Farmaceutische producten
Omzet 2024 * | 239 mln. 222 mln. | Omzet 2025 * | 299 mln. 278 mln. | Marktkapitalisatie | 2,27 mld. 2,11 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4 mln. 3,72 mln. | Nettowinst (verlies) 2025 * | 25 mln. 23,24 mln. | EV/omzet 2024 * | 9,48 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 7,58 x |
K/w-verhouding 2024 * |
587
x | K/w-verhouding 2025 * |
96,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,11% |
Recentste transcriptie over Aastrom Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 60 | 01-03-13 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 25-01-21 |
Michael Halpin
COO | Chief Operating Officer | 62 | 10-04-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 06-01-15 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 06-01-15 |
Robert Zerbe
CHM | Chairman | 73 | 16-01-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,47% | 88,14 mld. | |
+1,45% | 40,44 mld. | |
-14,43% | 32,24 mld. | |
+51,20% | 24,39 mld. | |
-14,85% | 15,59 mld. | |
-13,87% | 12,14 mld. | |
-7,87% | 12,18 mld. | |
-39,40% | 12,3 mld. | |
+5,62% | 8,87 mld. |